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Abstract 
Objective Sacral nerve modulation (SNM) is an established method for treating faecal 
incontinence (FI) if conservative measures fail. The International Consultation on 
Incontinence Questionnaire-Bowels (ICIQ-B) is a patient-completed symptom and quality of 
life assessment tool created by clinical experts with patient input. The purpose of this study 
was to use the ICIQ-B to evaluate the short-term efficacy of SNM in patients with FI.  
 
Method This was a prospective case series involving all patients with FI eligible for SNM at 
the University Hospital of Northern Norway (UNN). Patients were scored with ICIQ-B and St. 
Mark’s score at baseline and one month after SNM. Primary endpoint was efficacy defined 
as a change in ICIQ-B score from baseline to one month after SNM. Secondary outcomes 
were change in St. Mark’s score and the assessment of non-responders, defined as no 
change in score or higher score at one month, comparing the ICIQ-B to the St. Mark’s score.  
 
Results All 17 patients that were treated with SNM between February 2018 and October 
2018 were included in this study. All domains in the ICIQ-B showed a significant change in 
score from baseline to one month after SNM, except the domain concerning sexual impact. 
The bowel pattern score (0-21) had a mean change of 2.7 (95% CI: 1.2 - 4.2, p = 0.002), 
whereas the bowel control score (0-28) had a change of 6.8 (95% CI: 5.9 - 8.6, P < 0.001). A 
mean change of 1.7 (95% CI: 0.84 - 2.57, p = 0.001) was seen in the other bowel symptoms 
score (0-15). The quality of life score (0-26) showed a mean difference of 8.1 (95% CI: 4.5 - 
11.7, p < 0.001), and the overall quality of life score (0-10) presented a change of 2.7 (95% 
CI: 1.3 - 4.1, p = 0.001). The St. Mark’s score (0-24) had a mean change in score of 4.5 (95% 
CI: 3.0 - 5.9, p < 0.001). Seven patients (41%) were non-responders with the ICIQ-B 
compared to one (6%) in the St. Mark’s group. 
 
Conclusion A significant reduction in score one month after treatment with SNM was seen in 
5/6 domains of the ICIQ-B and with the St. Mark’s score. The ICIQ-B selected more non-
responders compared to St. Mark’s score, but the complexity of the ICIQ-B makes clinical 
applicability in the evaluation of efficacy after intervention uncertain. 
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Abbreviations and definitions  
 
AI     Anal incontinence - the impaired ability to control  
passage of gas or stool 
Bowel-habit diary   A diary registering frequency of bowel movements,  
stool consistency, use of antidiarrheal medication,  
incontinence episodes and more. Used prior to  
implantation of SNM and at follow-up  
Conservative treatment  Pelvic floor training, assisted defecation regimes and  
regulation of stool consistency 
DI   Double incontinence - concomitant urinary and anal 
incontinence 
Female sexual dysfunction  Problems related to sexual response, pain, orgasm and  
desire 
FI     Faecal incontinence - inability to control passage of  
stool  
ICIQ-B     The International Consultation on Incontinence  
Questionnaire-Bowels  
ICIQ-UI    The International Consultation on Incontinence  
Questionnaire-Urinary Incontinence  
OneStage-study   Multicentre study in Norway and Denmark where SNM  
is performed in one step without PNE 
PNE     Peripheral nerve evaluation  
SNM     Sacral nerve modulation 
St. Mark’s score   Validated questionnaire grading anal incontinence  
UNN     University Hospital of Northern Norway 
UI     Urinary incontinence - inability to control urine 








Faecal incontinence (FI) is defined as the inability to control defecation. It is a challenging 
and frequently occurring condition that can cause tremendous psychological, physical and 
social impact on a person’s life. The term faecal urgency is the lack of postponing defecation, 
while anal incontinence (AI) includes the inability to control flatulence (1-3). The prevalence 
of AI varies between 0.004% to 18% due to a lack of a proper definition of FI, variation 
between populations, and differences in type of data collected, but the prevalence of FI is 
approximately 0.7-10% (3-5). The aetiology of FI is multifactorial, but the condition can be 
seen more often in women with birth related injuries, patients with neurological illness, 
congenital malformations, sequela after surgery, anatomical factors, systemic illness and 
others (4). 
 
Many patients experience accompanying pelvic floor dysfunctions with urinary incontinence 
(UI) and female sexual dysfunction that also leads to altered lifestyle and reduction in quality 
of life (6, 7). However, patients treated with SNM for faecal and/or urinary incontinence 
have reported improvement of sexual function at follow-up, and studies suggest that SNM 
has an effect in women with sexual dysfunction (8).  
 
FI is a chronic condition that can be challenging to manage and occasionally needs a 
multidisciplinary approach. As described in international guidelines, the first line of 
treatment is conservative management that involves pelvic floor training, assisted 
defecation regimes and regulation of stool consistency. The patient is referred to a surgeon 
for an operative evaluation if outcome of these measures are inadequate after 3-6 months 
(1-3, 9).  
 
Conservative treatment in patients with FI proves to be efficient in nearly half of the 
individuals with the condition, however, some require surgery (10). Sacral nerve modulation 
(SNM) is a minimally invasive treatment for FI when a conservative approach fails (11). It was 
first described by Matzel in 1995 (12) and implemented at the University Hospital of 
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Northern Norway (UNN) in 1999 (13). The success rate during the first year after 
implantation is 79% with a long-term success rate of 84% after three years (11, 14). 
Internationally it is now a well-established second line treatment for FI, UI and double 
incontinence (DI; combined faecal and urinary incontinence), and it has also been tested in 
the management of constipation, lower urinary tract symptoms, chronic pelvic pain and 
sexual dysfunction in selected patients (1, 3, 8, 11, 13, 15-19).  
 
The surgical procedure of SNM 
The procedure of SNM is performed in the operating theatre under sedation, general- or 
local anaesthesia. One or more of the sacral foraminas are cannulated and an electrode is 
placed through the sacral foramina along the sacral nerve plexus. The electrode is attached 
to a neurostimulator, providing a pulsating current. An “anal wink” where the external anal 
sphincter contracts indicates correct placement of the electrode (20, 21). The pacemaker 
system creates a continuous low threshold voltage that affects the sacral nerve plexus that 
controls the functions of the pelvic floor (13, 22). Suboptimal placement of the electrodes to 
the sacral nerve is one of the several factors that may contribute to treatment failure. 
Therefore, a European group of colorectal surgeons and urologists standardized the surgical 
method of electrode placement in 2016. Prior to this, the surgical technique varied 
nationally and internationally (22).  
 
SNM can be performed in a two-step procedure (13, 23) where the first step is a three-week  
test phase, known as peripheral nerve evaluation (PNE). During this phase, the electrode is 
connected to an external pacemaker. The purpose of this part is to determine whether or 
not the patient is a suitable candidate for SNM. Successful PNE is defined as a reduction in 
faecal incontinence episodes of 50%, and the patient is then offered implantation of a 
permanent pacemaker (13, 22). Due to the high success rate (24) and the international 
standardization of the surgical method (22), there is currently a multicentre study in Norway 
and Denmark, known as the OneStage-study, where the procedure is performed in one step 
without PNE (25). This is thought to be more beneficial for the patients as there is one 
surgical procedure instead of two, in addition to less risk for infection in the site of 
implantation.  
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Mechanism of action 
SNM is a method of treating bowel and/or bladder dysfunction by electrically stimulating the 
nerve roots of the sacral spinal in order to modulate the neural pathway (11). The exact 
mechanism on how SNM works is not fully understood as there are various aetiologies for FI, 
but there are several hypothesis. The nerve fibres S2-S4 in the sacrum have autonomic 
activity on the left colon, rectum and internal anal sphincter. The pudendal nerve is 
controlled by the somatic fibres and there are afferent sensory nerves innervating the 
internal sphincter and afferent sensory somatic nerves innervating the external sphincter 
and the pelvic floor (21). SNM can therefore modulate both efferent and afferent somatic 
and autonomic nerves (figure 1). A thought is that stimulation of the pudendal somatic 
afferent nerve fibres activate somatic afferent fibres that enhance internal anal sphincter 
activity and inhibit activity of the colon (21). 
 
 
Contraindications and adverse effects  
Absolute contraindications for SNM involves need for MRI and inability to control the device 
when going through the test phase. Relative contraindications are patients with a complete 
Figure 1: Hypothesis on how SNM works (21) 
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spinal cord injury, a rapidly progressing neurological illness, pregnancy or abnormal anatomy 
of the sacrum (11). 
 
SNM is considered as a safe surgical procedure, however, unwanted events do occur. The 
most common complication is pain in the implant site. This occurs in approximately 30% of 
patients. Infection in the site of implantation, paraesthesia and pain in the leg or buttock are 
other less common adverse events of SNM (11, 26). 
 
Evaluation of treatment efficacy 
Despite success in the majority of patients receiving SNM, treatment fails in some and there 
is no defined preoperative examination that can predict outcome (27). Suboptimal 
placement of the electrodes is one of the several factors that may contribute to treatment 
failure (22). Another thought is that the current methods of evaluation are uncapable of 
determining who will have effect with SNM (responders) and efficacy. 
 
The efficacy of SNM is currently evaluated based on different incontinence scores like the St. 
Mark’s score and bowel-habit diaries (6, 28). Several studies use the fixed ³50 % reduction in 
incontinence episodes as an indicator for a successful result of SNM (6, 14, 24, 27, 29, 30). 
Based on this benchmark, a patient defined to have a successful result may experience  
incontinence episodes which can still greatly interfere with quality of life. By only evaluating 
reduction in incontinence episodes as a measurement for success, the true efficacy of 
treatment may not be accurately reflected. A reduction in incontinence score after 
treatment is also a commonly used method to estimate efficacy, but a defined cut-off value 
for successful outcome and failure is not defined (6). The lack of standardization in 
evaluation of outcome makes research on FI challenging (14, 28). Failure to involve patients 
in the creation of the forms may also exclude important concerns to the patients (31).  
 
The International Consultation on Incontinence Questionnaire-Bowels (ICIQ-B) is a relatively 
new patient-completed questionnaire subdivided into several categories, and is thought to 
give a more detailed picture of the symptoms and outcome after treatment for FI 
(attachment 1, table 2).  
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Objective 
The aim of this study was to use the ICIQ-B to evaluate the short-term efficacy of SNM in 
patients with FI, treated at UNN Tromsø in 2018. Primary endpoint was defined as a change 
in ICIQ-B score one month after surgical implantation of the pacemaker. In addition, the 
following secondary endpoints were assessed: 
1. Change in St. Mark’s score from baseline to one month in all patients with FI treated 
with SNM. 
2. Assess the number of responders versus non-responders using all domains of ICIQ-B 
compared to St. Mark’s score, were non-responders were defined as an unchanged 
or increased score one month after surgical implantation.  
 
Restrictions to this trial 
This study investigated the effect of treatment one month after implantation of the 
electrical stimulator. Many patients are suffering from DI, but this trial is limited to the 
effects of SNM on FI. Bowel-habit diaries, Wexner incontinence score and a questionnaire 
related to urinary incontinence (ICIQ-UI) were completed by the majority of patients as a 
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Patients and methods  
 
Study design and setting 
The present study was a prospective case series under the Department of 
Gastroenterological Surgery at UNN Tromsø, which is affiliated with the Norwegian National 
Advisory Unit on Incontinence and Pelvic Floor Health. The goal of this unit is to facilitate 
treatment across the various health care professionals while maintaining focus on 
symptoms, expectations and possible health benefits (32). Since 2012 it has been the leading 
pelvic floor unit in Norway and is an interdisciplinary centre that treats patients with pelvic 
floor disorders.  
 
In this study, all surgeries were performed at UNN Tromsø and the eligible patients were 
followed up at the surgical outpatient clinic in either UNN Narvik or UNN Tromsø. 
 
Table 1: Eligibility criteria 
* Defined as anal contraction when stimulating  three or more electrodes, with one <1,5 volt.  
 
Study population 
The study population contained all consenting patients of age 18 or older treated with SNM 
in 2018 (table 1). A St. Mark’s score greater than 8 points with weekly episodes of passive 
and/or urge FI and failed customized conservative treatment over six months were criteria 
for inclusion. Patients with peroperative success were also entered in the study. Exclusion 
criteria was perioperative lack of successful stimulation. 
 
All patients in this trial were a part of the ongoing OneStage-study at UNN Tromsø. 
Approximately half the patients were randomized (blinded) and given minor stimulation 
Inclusion criteria Exclusion criteria 
Informed consent 
18 years or older 
St. Mark’s score > 8 and weekly episodes of passive 
and/or urge FI 
Failed customized conservative treatment over the 
course of 6 months 
Peroperative successful stimulation* 
Perioperative lack of successful stimulation 
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with the pacemaker the first month according to the OneStage-study design. As the 
OneStage-study is not completed as the paper is being written, it is not possible to 
determine what patients received complete stimulation versus minor stimulation.  
 
Variables 
ICIQ-B as a method for evaluating treatment effect  
ICIQ-B is a psychometric patient-completed questionnaire on FI created by a team of 
multidisciplinary clinical experts through the ICIQ project (31). This was based on a study to 
identify items required for a comprehensive symptom and quality of life assessment tool 
from a patient’s point of view. Highlighted issues from patient interviews were 
unpredictability, toilet location, coping strategies, embarrassment, isolation and social 
impact (33). The form consists of 21 questions that scores the patient’s symptoms based on 
bowel control, bowel pattern and quality of life, as well as four unscored questions focusing 
on concerns from a patient or clinical perspective (attachment 1). Every question has a 
section where the patient can range how bothersome the given symptom is on a score from 
0-10. This is a supplement to attain bigger insight to the patient’s problem, but is not a part 
of the final score (31). The ICIQ-B has been translated to Norwegian, but is not yet published. 
 
Formally, ICIQ-B gives a score on the three domains; bowel pattern, bowel control and 
quality of life. Questions regarding bowel symptoms and sexual functions were included in 
the making of ICIQ-B due to their clinical efficacy and significance to symptomatic patients, 
but are not the formal psychometric properties in the questionnaire (31). This study wanted 
to thoroughly investigate all the aspects, and created therefore five main domains of the 
ICIQ-B in addition to a subdomain relating to quality of life termed “overall quality of life” 
(table 2). This works as a visual analogue scale (VAS) assessing how much the bowel 
interfere with everyday life, scored from 0-10 (question number 23 in ICIQ-B). Since the ICIQ-
B stands out from other questionnaires on FI by emphasizing on quality of life, it was 
considered important to look at this part separately. Therefore, this study used a total of six 
variables covering the ICIQ-B.  
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Table 2: Variables used in this study 
*A higher score indicates increasing symptoms. 
**Subdomain of the domain “Quality of Life”; acts as a visual analogue scale (VAS). 
 
St. Mark’s score as a method for evaluating treatment effect 
St. Mark’s score is a validated questionnaire that is based on symptoms the past four weeks, 
and grades frequency, type of incontinence, use of pads, and to what extent the condition 
affects lifestyle (28). A score of zero means no leakage and a score of 24 means complete 
incontinence (attachment 2). This method of evaluating patients is acknowledged 
internationally and the questionnaire has been translated in Norwegian (34). The St. Mark’s 
score has been used to assess patients treated with SNM, however, it does not incorporate 
aspects on quality of life (6, 15, 24, 28, 34, 35).  
 
Follow-up and data collection 
Scoring of symptoms with ICIQ-B and St. Mark’s score was done at the day before the 
surgery. Patients were either seen at the surgical outpatient clinic or contacted by a trained 
nurse by telephone one month after implantation to complete ICIQ-B and St. Mark’s score.  
 





ICIQ-B score    
Bowel pattern Bowel movements in 24 hours, nightly bowel 
movements, urgency, use of antidiarrheal medication, 
pain 
0-21 5 
Bowel control Underwear staining, use of pads, leakage of 
liquid/solid stool, flatus leakage control, mucus 





Bristol Stool Scale, straining, fear of having a bowel 
accident 
0-15 3 
Sexual impact  Restriction on sexual activities 0-5 1 
Quality of life 
 
 
Overall quality of life**  
Embarrassment, toilet location awareness, having to 
plan according to bowels, isolation 
 






St. Mark’s  score Frequency of solid and liquid stool, flatus leakage, 
change in lifestyle, the use of pads, use of 
antidiarrheal medication, ability to prolong defecation 
with 15 minutes 
0-24 7 
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The patients’ electronic journal (DIPS) were investigated to attain the aetiology of the 
incontinence, in addition to retrieve the scanned file with St. Mark’s score. Data were 
collected prospectively, and the completed ICIQ-B questionnaires were delivered 
confidentially to the investigator for analysis.  
 
Ethics 
This patient group is known to have various degrees of mistrust towards the health care 
system, and many patients have been struggling with their health for years. Incontinence 
contributes to intimate and embarrassing problems that can affect relationships, family, 
work and how they are viewed by society. Treating patients with this unmentionable 
condition requires discretion, frequent follow-up and high level of clinical experience. 
Patients were exclusively followed up by specialized nurses in this field.  
 
This trial was a project under the already occurring OneStage-study at UNN Tromsø, and 
patient consent was retrieved through the OneStage-study (see attachment 3-5). A second 
form of consent was not created, as this project was a quality assertion on a new 
questionnaire with no additional data collection. Because this was a part of the OneStage-
study and 50% of the patients were treated with minor stimulation initially, it was 
anticipated to detect a lower reduction in symptom scores than otherwise expected.  
 
Statistical methods 
Demographic data was retrieved through descriptive analysis and are presented with 
frequency tables, mean, standard deviation (SD), median and interquartile range (IQR). 
Categorical variables are listed with frequency (n) and the respective percentage. When 
comparing two groups, the paired samples T-test was used to analyse outcome variables and 
are presented as mean and standard deviation (SD). Difference of mean was presented with 
95% confidence interval (CI). Nonparametric tests were used when assumptions were not 
met. All analysis were completed with SPSS statistical software (version 25) with a 
significance level of p <0.05.  
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Responders versus non-responders 
A non-responder was defined as unchanged or increase in score one month after surgical 
implantation in one or more of the domains in the ICIQ-B or St. Mark’s score. We expected 
more non-responders using the ICIQ-B as this questionnaire contains more questions 
regarding quality of life, and also 50% of the patients were assigned to minor stimulation in 
the OneStage-study. The domain concerning sexual impact was omitted from the evaluation 
of responders versus non-responders, as the patients were recommended to avoid sexual 
intercourse during the first six weeks after surgery. 
 
Wilcoxon Signed Rank Test was used to identify responders versus non-responders by 
determining if median in the distribution of differences were equal or different than zero. If 
the difference was equal to zero, it was defined as no difference in treatment prior to 
surgery compared to after surgery. A negative change in score (negative rank) meant better 
outcome, as a lower score indicates less symptoms. A positive change in score (positive rank) 
meant worse outcome, as an increase in score meant more symptoms. In other words, 
patients with a difference ³0 between baseline at one month were considered non-
responders, while patients with a difference <0 were responders to SNM treatment.   
 
  




A total of 17 patients received treatment with SNM at UNN Tromsø between February 2018 
and October 2018, and all were included in the study. Patients completed the ICIQ-B and St. 
Mark’s score the day of surgery, in addition to one month postoperatively, either at the 
outpatient clinic or by telephone.  
 
The mean age was 52.8 (SD 14.4) and 16/17 participants were female. Nearly half the study 
group (47%) had a previous obstetric history as a cause for FI, while 18% had a neurological 
aetiology (multiple sclerosis, cauda equina syndrome). The remaining 35% of patients had 
other or idiopathic cause for FI (table 3).  
 
Table 3: Demographic data 
n = number of patients, SD = standard deviation, IQR = interquartile range 
 
The primary endpoint in this study was change in ICIQ-B one month after implantation of 
SNM. All domains, except for the sexual impact score, had significant change in score from 
baseline to one month (table 4, figure 2). Significant difference in St. Mark’s score was also 
found (table 4, figure 3).  
 
 N (%) Mean (SD) Median (IQR) 
Sex 17   
Female 16 (94)   
Male 1 (6)   
Age (years)  52.8 (14.4) 52.0 (40-68) 
Aetiology    
Obstetric 8 (47)   
Neurologic 3 (18)   
Idiopathic FI/other 6 (35)   
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Outcome of ICIQ-B and its respective domains 
Bowel pattern score 
Patients scored with a mean of 11.7 (SD 2.8) at baseline compared to 9.0 (3.1 SD) at one 
month, resulting in a mean change of 2.7 (95% CI: 1.2 – 4.2) and proving to be significant 
with p = 0.002 (table 4, figure 2). Of the 17 patients, 14 patients (82%) showed a score with 
better outcome one month after surgery. One patient (6%) had no change in score, while 
two patients (12%) had a worse score after treatment (table 5, figure 5).  
 
Table 4: Differences in ICIQ-B domains and St. Mark's score at baseline and one month 
See table 2 for definition and score for the respective domain. 
Values are presented as mean and SD (standard deviation). Mean difference (with 95% confidence interval) represents 
difference in score at baseline and at one month and was achieved by paired samples T-test, where a p-value < 0.05 was 
considered statistically significant. 
 
Bowel control score 
With a mean of 20.9 (2.9 SD) at baseline and 14.1 (SD 4.4) at one month, there was a 
significant difference in score of 6.8 (95% CI: 5.0 – 8.6), p < 0.001 (table 4, figure 2). Only one 
(6%) patient had an unchanged score (6%), while 16 patients (94%) had a lower score one 
month after treatment (table 5, figure 5). 





Mean SD Mean SD   
Bowel pattern 
score 
11.7 2.8 9.0 3.1 2.7 (1.2 – 4.2) 0.002 
Bowel control 
score 
20.9 2.9 14.1 4.4 6.8 (5.0 – 8.6) < 0.001 
Other bowel 
symptoms score 
9.9 1.4 8.2 2.3 1.7 (0.84 – 2.57) 0.001 
Sexual impact 
score 
2.9 1.6 2.7 1.7 0.2 (0.3 – 0.7) 0.332 
Quality of life 
score 
21.8 3.1 13.7 7.6 8.1 (4.5 – 11.7) < 0.001 
Overall quality of 
life 
8.5 1.4 5.8 3.5 2.7 (1.3 – 4.1) 0.001 
St. Mark’s score 17.3 2.0 12.8 3.7 4.5 (3.0 – 5.9) < 0.001 
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Other bowel symptoms score 
Score at baseline was a mean of 9.9 (SD (1.4) compared to 8.2 (2.3 SD) at one month, 
resulting in the mean difference of 1.7 (95% CI: 0.84 – 2.57) being significant, p = 0.001 
(table 4, figure 2). Two patients (12%) had a better score prior to treatment than after. The 
reminding 15 patients (88%) had had a score indicating less symptoms at one month (table 
5, figure 5).  
 
Figure 2: Mean score of the six various domains in the ICIQ-B at baseline and at one month after SNM 
 
 
Sexual impact score 
The mean score at baseline was 2.9 (SD 1.6) compared to a slightly lower mean of 2.7 (SD 
1.7) at one month, showing the mean difference to be 0.2 (95% CI: 0.3 – 0.7). With a p = 
0.332 (table 4, figure 2). However, patients were recommended to avoid sexual intercourse 
six weeks after implantation, confirming the result where ten (59%) did not have a change in 
score and two patients (12%) had a worse score at one month (table 5). Therefore, this 
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Quality of life score 
This score showed the greatest change compared to the other domains. With a mean 
difference of 8.1 (95% CI: 4.5 – 11.7) provided by a mean at baseline of 21.8 (SD 3.1) and 
13.7 (SD 7.6) at one month, there was a significant change in quality of life with p < 0.001 
(table 4, figure 2). Of the 17 patients, one patient (6%) had the same score, while 16 (94%) 
were had better outcome at one month (table 5, figure 5).  
 
Overall quality of life 
There was a significant change from a mean of 8.5 (SD 1.4) at baseline to 5.8 (SD 3.5) at one 
month, resulting in a mean difference of 2.7 (95% CI: 1.3 – 4.1), p = 0.001 (table 4, figure 2). 
A total of five patients (29%) showed no response to treatment, where four (24%) of these 
had an unchanged score at one month. The 12 remaining patients (71%) had better outcome 
on this subdomain (table 5, figure 5).  
 
Figure 3: Mean score evaluated with the St. Mark’s Score at baseline and at one month after SNM 
 
 
Outcome of St. Mark’s score 
St. Mark’s score showed a change in the mean score at baseline of 17.3 (SD 2.0) and at one 
month 12.8 (SD 3.7). The mean difference was 4.5 (95% CI: 3.0 – 5.9), and was considered 
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treatment according to this scoring method. Of the 17 patients, 16 (94%) had better 
outcome at one month, while only one patient (6%) had an increased score after treatment 
(table 5, figure 5).  
 
Table 5: Ranks of observed differences in the various domains of ICIQ-B and St. Mark’s Score 
*Wilcoxon Signed Rank Test. 
#: patient number in data bank. 
 
Responders versus non-responders 
After detecting the number of responders versus non-responders, the patients who had 
worse or no difference in outcome were identified and labelled using “#“ followed by the 
patient’s given number in the data bank (table 5, figure 4). This was done to see if a patient 
was non-responding in multiple domains in addition to comparison to responders and non-
responders in the St. Mark’s score.  
 
A total of seven patients (41%) were considered non-responders (# 1, 2, 6, 9, 14, 15, 16) in 
one or more domains using the ICIQ-B compared to one (6%) non-responder (#15) using the 
St. Mark’s score (table 6). The sexual impact score was excluded as previously described.  
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p-value* 0.003 0.000 0.001 0.340 0.000 0.002 0.000 
 ICIQ-B St. Mark’s score 
Responders (%) 10 (59) 16 (94) 
Non-responders (%) 7 (41) 1 (6) 
Total 17 17 
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With the five significant domains of the ICIQ-B, a total of four patients (#1, 2, 9, 16) were 
considered non-responding in one of the domains. Another two patients (#6, 15) were non-
responders in two domains, while one patient (#14) had no difference or increased 
symptoms in four domains. In comparison, St. Mark’s score had only one non-responder 
(#15) in total. This patient was also non-responding in two domains using the ICIQ-B, which 
was interestingly the bowel pattern score and overall quality of life. 
 
Figure 4: Graphical representation of responders and non-responders after treatment with SNM using ICIQ-B 



































Distribution of responders vs. non-responders
Responder (better outcome) Non-responder (no difference) Non-responder (worse outcome)
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Discussion 
 
To our knowledge, this is the first study evaluating the efficacy of SNM using the ICIQ-B. In 
this study, we found that five out of six domains in the ICIQ-B showed significant change one 
month after SNM, except for sexual impact. There was also a significant reduction in St. 
Mark’s score. Seven patients (41%) were non-responders in one or more domains using the 
ICIQ-B, compared to a single patient (6%) using the St. Mark’s score.  
 
ICIQ-B as a method for evaluating efficacy of SNM 
Bowel pattern score 
With the bowel pattern score focusing on daily and nightly bowel movements, urgency, pain 
and use of antidiarrheal drugs, more than 80% of patients had a reduction in symptoms one 
month after treatment. Despite of this, the mean reduction in score was only three out of 21 
points (14%). The reduction was lower than expected. It appears in published literature that 
bowel-habit diaries are mainly used for detecting change in FI episodes to evaluate efficacy 
of SNM, not change in bowel pattern. Bowel-habit diaries contain information on several of 
the topics in this domain, like urgency and frequency of bowel movements, but are not used 
as measures of outcome after SNM (14, 25, 36). The St. Mark’s score does not register 
frequency of bowel movements, but involves urgency where patients can answer “yes” or 
“no” if they can postpone defecation for 15 minutes (28). The ICIQ-B grades urgency on a 
scale from 0-4, and gives therefore a more accurate and graded evaluation, but also 
eventually a lower change in score compared to the St. Mark’s score.  
 
The St. Mark’s score also includes the use of antidiarrheal drugs, presented in a categorical 
manner. The ICIQ-B measures the use of antidiarrheal drugs on a scale from 0-5. This 
contributes to a skew comparison in scores in the same fashion as urgency already 
described. Moreover, the patients are also supposed to continue conservative treatment 
including antidiarrheal medications even after SNM. The evaluation of pain as in the ICIQ-B 
in patients with FI treated with SNM, has to our knowledge not been described previously, 
but may be an important aspect as some studies have shown that pain is a common 
complaint after SNM (6). 
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In summary, the usefulness of the bowel pattern score in the ICIQ-B in the evaluation of 
efficacy of SNM is unknown. The ICIQ-B gives a more detailed grading of symptoms than the 
St. Mark’s score. Urgency stands out as the important aspect of the bowel pattern score, 
compared to the remaining topics in this domain which may be less relevant in evaluating 
the efficacy of SNM. The change in urgency can ultimately be masked amongst less 
important questions and the associated large width in scale in the bowel pattern domain.  
 
Bowel control score 
The bowel control score showed that more than 90% of the patients experienced a decrease 
in incontinence symptoms like soiling, ability to hold soft or hard stool, ability to control 
flatulence and mucus, as well as passive leakage. A mean reduction in score was nearly 
seven out of 24 points (30%). This value appear to be comparable to other studies using the 
traditional questionnaires like St. Mark’s score and Cleveland Clinic Incontinence Score (6, 
14).  
 
The St. Mark’s score includes three of the seven questions in this domain, which are leakage 
of soft and hard stool and leakage of flatulence. The remaining questions in the ICIQ-B may 
not contribute to any additional information with regards to treatment efficacy of SNM, but 
contributes to a more complex and complicated questionnaire to complete for the patients 
and for interpretation of efficacy.  
 
Other bowel symptoms score 
Nearly 90% of patients experienced better outcome in the other bowel symptoms domain, 
which was the consistency of stool (Bristol Stool Scale), straining and fear of having a bowel 
accident. With the maximum score of 15, the change after one month was only two points 
(13%). Perhaps it is too early to evaluate the fear of having a bowel accident at this stage. It 
is likely that fear is still present in patients with remaining incontinence episodes, even if 
frequency is reduced or eliminated as it is believed that it takes time to break a negative 
pattern and trusting the restoring natural functions of the body.  
 
This domain also contains various components on FI that are not related. A large reduction 
in the Bristol Stool Scale may ultimately mask an unchanged or increased score in fear of 
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having a bowel accident, although the scale is a target for conservative treatment before 
surgical intervention and related to use of antidiarrheal medication already evaluated in the 
bowel pattern score. 
 
The usefulness of ICIQ-B on this domain at one month is unknown. However, it is believed 
that fear will decrease over time as incontinence episodes diminishes, so this score should 
be further investigated at one year follow-up. 
 
Sexual impact score 
The sexual impact score showed no difference in outcome after one month, and similar 
findings have been described (24). Prior to surgery, patients were advised to avoid sexual 
activity during the first six weeks after surgery. It was therefore not expected to get a change 
in score after one month. A change in the sexual impact score may therefore be determined 
with a longer period of follow-up. However, research suggest that SNM can alter the 
pudendal nerve function and can cause an increase in pelvic blood flow via stimulation of 
parasympathetic fibres that can ultimately improve sexual function (8, 37). Long-term effects 
of SNM on female sexual dysfunction is still unknown (7, 8, 38).  
 
Involving sexual impact in the questionnaire is an asset with the ICIQ-B as it evaluates more 
of the dysfunctions of the pelvic floor. However, the ICIQ-B does not take urinary 
incontinence into consideration. Approximately 75% of women have concomitant UI and 
SNM is proven to be an effective treatment of both UI and DI (24). Urinary symptoms should 
have been incorporated in the questionnaire for assessing the efficacy on pelvic floor 
function as a whole after treatment. Incorporating urinary function as well as sexual function 
would have given a complete questionnaire to assess pelvic floor function after intervention. 
Anyhow, the ICIQ advisory board recommend to use other available questionnaires for 
urinary function (ICIQ-UI) (1). 
 
Quality of life 
Of the two domains relating to quality of life, 94% had better outcome on aspects regarding 
embarrassment, toilet awareness, interference with everyday life and isolation. This domain 
had a mean reduction of more than eight points, which was the greatest difference in score 
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of all domains in the ICIQ-B. Quality of life improvement that follows the functional 
progression of incontinence has been shown to correlate in published literature (6, 14, 39, 
40). Comparatively the same can be seen with the quality of life score and the bowel control 
score in the ICIQ-B. Furthermore, 71% showed an improvement when asked to scale their 
overall quality of life from 1-10, with a mean change in score of three points (30%).  
 
The quality of life score involves 26 questions with a mean reduction of eight points (31%), 
whereas the overall quality of life has ten questions with a mean reduction of three points 
(30%). Interestingly, both scoring methods were reduced with a third of the baseline score. 
In other words, the comprehensive quality of life score may not offer any additional 
information relating to treatment efficacy with ICIQ-B compared to the VAS or overall quality 
of life score. VAS scales have previously been proved accurate on evaluating the impact of 
urinary incontinence on quality of life (41). Having to answer many questions is tedious and 
bothersome to the patient. Perhaps this domain does not need all the questions on quality 
of life, as it appears that the simple VAS scale offers the same result in a single question.  
 
St. Mark’s score as a method for evaluating efficacy of SNM 
The St. Mark’s score showed that 94% of the patients had effect of SNM with a change of 
nearly five points (21%) in one month. This is less than what has been described previously, 
but it appears that no study has evaluated outcome at one month specifically, in short-term 
studies (14, 42). Another explanation for a less favourable outcome after one month is of 
course that half of the patients received minor stimulation only. 
 
St. Mark’s score focuses on the functional aspects of FI, and bases effect on objective 
measures. It was created by Vaizey et. al. as there was no scoring system evaluating the 
severity of FI with good reproducibility in published literature. In addition, objective 
comparison of outcome for both conservative and surgical treatments were lacking (28). This 
scoring method has been used in many recent studies (6, 14, 24, 40), but in comparison with 
the ICIQ-B, it has a less meticulous grading of symptoms and does not evaluate any quality of 
life aspects like fear and isolation (table 7).  
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Anyhow, a reduction in St. Mark’s score has been shown to correlate with quality of life (6), 
but does not solely give a detailed picture on what aspects are challenging like the ICIQ-B 
does. The St. Mark’s score should therefore be used in combination with other methods of 
evaluating quality of life.  
 
Responders versus non-responders  
The ICIQ-B manged to detect more non-responders compared to the St. Mark’s score. The 
ICIQ-B had a total of seven non-responders (41%) compared to a single non-responder (6%) 
with the St. Mark’s score. Interestingly, five non-responders were identified based on the 
domains specific on quality of life. It is also noteworthy that approximately half of the 
patients had minor stimulation due to assignment in the OneStage-study, and were 
expected to be non-responders. This highlights the challenges using any questionnaires 
evaluating treatment efficacy after intervention for functional disorders like faecal 
incontinence. It has been reported that approximately 30% of patients with FI have better 
treatment outcome with SNM based on a substantial placebo effect (6, 36, 43). Due to 
beliefs and high level of expectation, it is already established that the placebo effect are high 
in patients with chronic gastrointestinal disorders (36), and might be a confounding factor in 
this trial as significant effect was found in such a short time.   
 
Comparatively, long-term results show that treatment fails in approximately 30% of patients 
receiving treatment with SNM (14, 19), similar to what the ICIQ-B revealed at one month. 
Remarkably, there was only one patient non-responding in the bowel control domain, and 
one non-responding in the St. Mark’s score. One of the main goals of SNM is to treat 
incontinence episodes, but with the complexity of FI it seems like improvement in 
incontinence episodes does not solve all the problems for the affected patient. Patients with 
FI need a multidisciplinary approach where the ICIQ-B can contribute as an important tool in 
understanding the symptoms and the efficacy of treatment. However, when evaluating 
efficacy of SNM, it might be too complex and extensive, but further research with more 
patients and longer follow-up is needed in order to conclude.  
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Should the ICIQ-B be the new method of evaluating treatment efficacy with SNM? 
The ICIQ-B contributes with many key topics that cannot be found in a single questionnaire. 
It involves important sections that grades urge, assess stool consistency, sexual impact, fear 
and quality of life (table 7). As this study shows, it detects many other aspects related to FI 
other than change in incontinence episodes.  
 
Like previously stated, the majority of patients with FI also have UI. The ICIQ-B lack 
evaluation of these symptoms. Adding assessment of UI would have given a complete 
questionnaire for assessing the efficacy on pelvic floor function after treatment.   
 
Overall, the ICIQ-B seems to be a too comprehensive method for evaluating efficacy of SNM, 
but shows significant change in outcome comparable to the St. Mark’s score. The 
questionnaire seems to involve too many questions with high variety that causes important 
topics to drown amongst insignificant questions in the domain. Also, a long questionnaire 
can be bothersome to patients and is not suitable for use in follow-up via telephone. The 
ICIQ-B is an important tool in evaluating incontinence, but not in the evaluation of treatment 
efficacy at one month. Perhaps the ICIQ-B would be more useful in a multidisciplinary 
baseline evaluation of complex patients or in treatment failure, compared to standard 
follow-up after intervention.  
 
 Table 7: Strengths and limitations with the ICIQ-B and St. Mark's score. 
 
Strengths of this trial 
This study was a prospective evaluation of treatment efficacy using a relatively new 
questionnaire, ICIQ-B. There are established methods for clinical assessment on FI, like 
Pescatori score, Cleveland Clinic Incontinence Score, bowel-habit diaries and St. Mark’s score 
 ICIQ-B St. Mark’s score 
Strengths  Patient completed 
Created with input from patients 
Evaluates many aspects on quality of life 




Suitable for objective comparison  
 
Limitations Long questionnaire 
No published studies using the form 
Not published in Norway 
Absent evaluation of UI 
Limited evaluation on quality of life  
Absent evaluation of sexual impact  
Absent evaluation of UI 
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(28). All these evaluate the functional problems that patients have based on the clinicians 
evaluation and expertise. So far, a detailed self-reporting evaluation on experienced 
symptoms and quality of life is lacking, therefore it has been important to determine if the 
ICIQ-B can contribute in a more detailed matter in determining the treatment efficacy of 
SNM. 
 
Limitations of this trial 
This study included all patients treated for SNM at UNN Tromsø in 2018, which was a total of 
17. This is a small population sample and follow-up time was limited to one month. Most 
research available on the efficacy of SNM on FI carries out small prospective and 
retrospective case series with few randomized controlled trial, and follow-up in existing 
literature is based on a mean follow-up period between six and 12 months (14). This study 
showed nonetheless a significant decrease in symptoms and increase in quality of life 
already after one month.  
 
None of the available questionnaires have a defined cut-off value defining success, and 
efficacy was simply defined as a reduction in score (responder). The St. Mark’s score also 
assess the function over a course of the past four weeks. In order to get a more accurate  
value of the ICIQ-B, it would be necessary to evaluate each question separately.  
 
In addition, this was a part of an ongoing randomized trial where half of the patients had 
minor stimulation and were expected to be non-responders. Further analysis after 
completing the trial and identifying the patients in the non-stimulation group, will give 
additional information about the genuine value of the questionnaires, with true non-
responders and probably greater change in score.  
 
Another limitation is that the validation of the ICIQ-B is not published and available for 
clinical use in Norway, and the current translation of questions may not correctly represent 
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Conclusion 
The ICIQ-B showed a significant change in five out of six domains one month after 
implantation. There was also a substantial reduction in the St. Mark’s score for the same 
duration of follow-up. Seven patients (41%) proved to be non-responders in one or more 
domains using the ICIQ-B, compared to a single patient (6%) using the St. Mark’s score. 
 
Using the ICIQ-B in evaluation of treatment efficacy adds important points on fear, a more 
detailed evaluation of urgency, consistency of stool, and sexual impact, but lacks assessment 
of UI. However, the ICIQ-B is more complex to complete for the patients and for 
interpretation in clinical practice, thus making the clinical applicability uncertain.   
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Appendices 
 
Attachment 1: The International Consultation on Incontinence Questionnaire-Bowels 
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Attachment 2: St. Mark’s score 
 
 Never Rarely Sometimes Weekly Daily 
Incontinence for solid 
stool 
0 1 2 3 4 
Incontinence for liquid 
stool 
0 1 2 3 4 
Incontinence for gas 0 1 2 3 4 
 No Yes 
Need to wear a pad or 
plug 
   0 2 
Taking constipation 
medicines 
   0 2 
Lack of ability to defer 
defecation for 15 minutes 
   0 4 
 
Never = no episodes in the past four weeks 
Rarely = 1 episode in the past four weeks 
Sometimes = > 1 episode in the past four weeks but < 1 per week 
Weekly = 1 or more episodes a week but < 1 per day 
Daily = 1 or more episodes a day 
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Attachment 4: Patient conscent  
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Attachment 5: Personregister UNN 
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Grade 1 
Reference: Thin NN, Horrocks EJ, Hotouras A, Palit S, Thaha MA, Chan CL, et al. 
Systematic review of the clinical effectiveness of neuromodulation in the treatment 
of faecal incontinence. Br J Surg. 2013;100(11):1430-47.  
Design:  Systematic review 
Level of documentation: 2b 
GRADE: B 
Objective Material and method Results Discussion/comments 
Various neuromodulation 
therapies have been used in 
treating patients with faecal 
incontinence (FI) over the past 
18 years, and sacral nerve 
stimulation (SNS) is the most 
recognised method. Other 
methods are percutaneous 
tibial nerve stimulation (PTNS) 
and transcutaneous tibial nerve 
stimulation (TTNS) 
 
The goal of this systematic 
review is to evaluate the clinical 
effectiveness of the various 
types of neuromodulation in 
treating FI.  
This was a systematic 
review that utilized 
Preferred Reporting Items 






Based Medicine reviews 
was used in reviewing 
literature.  
 
Inclusion criteria was 
studies from 1995 – 2012 
with permanent SNS, 
PTNS, and TTNS treatment. 
Non-English papers were 
only used if they provided 
an abstract with 
appropriate information. 
Each study included 
needed to have at least 10 
patients treated with 
permanent 
neuromodulation, and had 
to provide at least one 
outcome measure, as well 
as a clear follow-up 
interval. Exclusion was PNE 
or chronic testing phase of 
SNS.  
 
Primary outcome was the 
success rate of the given 
therapy where FI-episodes 
were reduced with ³50%. 
Secondary outcome was 
cure rates (100% reduction 
in FI-episodes). 
Authors used the 
PRIMSA-framework 
in order to keep a 
clear guidance on 
the methodology to 





61/321 articles on 
SNS were included 
in this review. 7 
articles on PTNS and 




the median success 
rates for SNS were 
for short terms 63, 
medium terms 58 
and 54 for long 
term. For PTNS the 
success rate was 
59% after 12 
months of follow-
up. It was shown 
that SNS lost 10% of 
its effectiveness 
after 5 years. 
 
There was an 
increase in quality-
of-life measures and 
Cleveland Clinic 
Incontinence Score 
in all of the 
neuromodulation 
techniques.  
This review presents summaries 
of the available therapy options 
in neuromodulation and the 
scores on short-, medium- and 
long-term basis. With a proven 
effectiveness of PTNS, it can be 
seen as a more cost-effective 
alternative in treating patients 
with FI without improvement 
after a conservative approach. 
 
Authors demonstrate a table of 
the different studies included in 
this review, and it shows that the 
majority of the studies are case 
series. 
 
Authors identify the risk of 
selection bias due to inclusion 
criteria of studies containing >10 
patients, as well as only English 
written articles. They argue that 
this prevents bias as it eliminates 
patient subpopulations and 
inexperienced investigators.  
 
There was a big heterogeneity in 
outcome measure, as well as 
different reporting styles. Authors 
comment that this made 
statistical formal synthesis 
impossible to accomplish.  
 
The evidence base for PTNS and 
TTNS was poor since it consisted 
mostly of case series involving 
few patients and a limited follow-
up period.   
 
Two of the authors are advisers 
to Medtronic, a medical company 
producing stimulators in SNS 
therapy.  
Conclusion 
SNS is a useful therapy in 
treating patients with FI and is 
proven to have a long-term 
effect. PTNS is proven to be 
efficient in treating FI, but no 
evidence supports its validity 
after 12 months. There is still 
uncertainty of the clinical 
effectiveness of TTNS due to 
lacking evidence. 
Standardization of outcome 
measures is recommended for a 
more accurate comparison in 
research on this topic.  
Country 
Various 
Year of data collection 
January 1995 – July 2012 
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Grade 2 
Reference:  Knowles CH, Horrocks EJ, Bremner SA, Stevens N, Norton C, O'Connell PR, et al. 
Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment 
of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, 
parallel-group, randomised controlled trial. Lancet. 2015;386(10004):1640-8.  










(PTNS) is an alternative 
to sacral nerve 
stimulation that is 
believed to be less 
invasive, more cost 
effective and is thought 
to lead to similar 
changes in the 
anorectal 
neuromuscular function 
in patients with faecal 
incontinence (FI). Data 
suggests it has 
beneficial outcomes in 
50-80% of patients 
treated, but its 
effectiveness has never 
been investigated to 
sham electical 
stimulation (placebo).  
The study wants to 
investigate short-term 
afficacy of PTNS 
compared to sham 
electrical stimulation in 
adults with FI.   













over 18 years 









either PTNS or 
sham 
stimulation 
once per week 


















227 out of 373 screed patients were randomly 
assigned into two groups to receive either PTNS 
(n=115) or sham stimulation (n=112). 12 patients 
withdrew from the study as they were not able 
to commit to the treatment programme, 2 
patients withdrew due to unrelated problems. 
 
 














































38% of the patients had a fully completed bowel-
habit diary in the PTNS group, and showed to 
have a >50% reduction in weekly FI episodes, 
compared to 31% of the patients in the sham 
group.  
 
Patients and investigators involved in evaluation 
of clinical outcome were masked to treatment 
allocation during the course of the involvement 
of the trial. Investigators performing the 
treatment procedure was not masked. 
Authors comment that 
placebo effect is high in 
patients with chronic 
deliberating gastrointestinal 
illnesses as they have higher 
levels of expectations. The 
authors had predicted this 
(estimated 35% vs. 31% in the 
study). Bowel-habit diaries 
can also lead to bias if 
unmasked.  
 
Authors discuss limitations 
that might relate to the 
negative outcome, such as a 
undefined outcome measure 
for FI. Prior to the study, all 
patients had received 
conservative therapy which 
was not formally standardized 
which might have created a 
variety in baseline 
characteristics. Also, patients 
could still use antidiarrheal 
drugs during the course of the 
study, and could ultimately 
affect the results of the study. 
 
Authors conclude that there 
is no significant difference in 
treating patients with PTNS 
compared to sham electrical 
stimulation. Previous 
systematic reviews have 
proven the contrary. This 
study focused on short term 
outcome, and therefore 
authors comment that if 
would be appropriate with 
further studies exploring 
long-term effects, as well as 
benefits in patients 
subgroups.   
 
Conclusion 
PTNS was not proven to 
have better clinical 
benefit compared to 
sham electrical 
stimulation treating 




Year of data collection 
2012-2013 
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Grade 3 
Reference: Vallet C, Parc Y, Lupinacci R, Shields C, Parc R, Tiret E. Sacral nerve 
stimulation for faecal incontinence: response rate, satisfaction and the value of 
preoperative investigation in patient selection. Colorectal Dis. 2010;12(3):247-53. 
Design:  Prospective cohort study 
Level of documentation: 2b 
GRADE: B 
Objective Material and method Results Discussion/comments 
Prior to treatment 
with sacral nerve 
stimulation (SNS) for 
faecal incontinence 





The objective of the 
study was to assess 
the value of these 
tests in patient 
selection to predict 
who would have 
greatest benefit of 
the treatment.   
  
Patients were included in the 
study and treated with SNS if they 
were between 18-75 years of age, 
had involuntary passage of solid 
or liquid faces minimum once per 
week, and refractory to medical 
treatment and biofeedback 
therapy. Previous surgery, 
malformations, IBD, stoma, 
chronic diarrhoea, and likelihood 
of non-compliance were exclusion 
criteria. Data was collected 
prospectively.  
 
Preoperative evaluation was 
based on patient characteristics. 
Physical examination and bowel 
habit diaries were completed 
over at least 15 days. Patients 
were also scored on urgency and 
the severity of FI with the 
Cleveland Clinic Continence 




examinations were also 
performed in every patient.  
Initial assessment lasted 10 days 
after implementation of 
temporary sacral nerve 
electrodes. Selection for 
permanent implantation was 
based on patient satisfaction and 
improvement based on bowel 
habit diaries. Patients were 
followed up at 3 months by 6 
monthly intervals.  
 
For statistics, the Mann-Witney 
U-test, Student’s t-test and X2 
tests were used. For analysis, 
Statview Software was used.   
41 females and 4 males 
with FI underwent 
treatment with SNS. Of the 
45 patients, 10 (22%) failed 
the temporary test, while 
testing was unsuccessful in 
3 (7%). Temporary 
stimulation was effective 
in 32 patients (71%) and 
proceeded to permanent 
implantation. 23 patients 
(51%) had a functioning 




There was no statistically 
significant difference 
between the preoperative 
evaluation of patients 
undergoing permanent 
implantation (n = 32) and 
not (n = 13), and those 
with (n = 23) or without (n 
= 13) a functioning 
stimulator. 
 
The results were 
considered good in 12 of 
the 23 patients with a 
functioning stimulator. 5 
patients reported 
satisfactory result and 6 
reported poor result. No 
statistically significant 
difference in patient 
characteristics was proved 
between patients with a 
good result (n = 12) and 
the rest (n = 32).  
Patients included in the study had met 
the criteria of FI and was refractory to 
other medical treatment. The study 
population consisted of men and 
women separated in to groups based 
on aetiology, which was obstetric or 
surgical trauma, idiopathic, neurologic 
or radiotherapy. Data was collected 
prospectively with follow-up after 3 
months and at 6 monthly intervals 
subsequently, with a mean follow-up 
time of 3 years or more. The study 
describes well the comparison in 
patient satisfaction. 
 
The authors discuss the complication 
rate of 34% and justifies the possible 
causes well. They also bring up the 
short test phase of 10 days, which is 
at the shorter end of the range of 10-
21 days recommended by other 
researchers on this topic.  
 
The authors also discuss how a 
preoperative selection would be cost-
effective, but how they  failed with 
the pre-treatment investigations used 
in this study. 
 
The authors refer to other studies that 
suggest that there are other methods 
of predicting outcome with temporary 
stimulation, but a discrepancy 
between objective success and 
subjective satisfaction has to be 
considered nevertheless.  
 
Conclusion 
The study concludes 
that tests for faecal 
incontinence prior to 
treatment with SNS, 
does not facilitate 
patient selection, nor 






Year of data collection 
June 2001 – January 
2007 
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Grade 4 
Reference: Duelund-Jakobsen J, van Wunnik B, Buntzen S, Lundby L, Baeten C, 
Laurberg S. Functional results and patient satisfaction with sacral nerve stimulation for 
idiopathic faecal incontinence. Colorectal Dis. 2012;14(6):753-9. 
Design: Cohort study 
Level of documentation: 2b 
GRADE B 
Objective Material and methods Results Discussion/comments 
Patient satisfaction has 
never been considered as 
a method of  evaluation 
in treatment with sacral 
nerve stimulation (SNS). 
This study investigates 
patients with faecal 
incontinence (FI) treated 
with SNS to see if there is 
a relationship between 
patient satisfaction and 
clinical outcome assessed 
by symptom scores and 
bowel-habit diaries.  
Patients treated with SNS for 
idiopathic faecal incontinence (IFI) in 
Denmark and The Netherlands were 
included in the study.  
 
Patients were considered to have IFI if 
they had no previous history of 
anorectal surgery, neurological 
disorders, diabetes, spinal cord injury, 
thyroid diseases or larger sphincter 
defects. 
 
A total of 158 patients were 
considered to have IFI out of the total 
of 342 patients with faecal 
incontinence (remaining non-
idiopathic patients). 129 of the 158 IFI 
patients were receiving active SNS 
therapy at the most recent follow-up, 
and these data were compared to 
baseline data from the European 
Sacral Nerve Stimulation Database 
and the Maastricht University Medical 
Centre local database.  
 
Follow-up was performed at 1, 3, 6 
and 12 months after implantation and 
yearly thereafter. 
 
Treatment outcome was evaluated 
based on incontinence/bowel scores 
and patients were asked if they were 
satisfied with the treatment. 
 
Mann-Whitney U-test and Fisher´s 
exact test were used for statistical 
comparison between groups. 
Correlation between improvement in 
incontinence episodes and patient 
self-reported satisfaction with bowel 
function, social function and quality of 
life was assessed by the Pearson 
correlation coefficient and 95% CI.  
The results 
showed that the 
number of FI 
episodes were 
undoubtedly 






were all satisfied. 
Satisfaction rate 
decreased with an 
increasing number 
of FI episodes. 
Interestingly, 
46%of patients 
with more FI 
episodes at the 
time of follow-up 
than at baseline 
were still satisfied. 
These patients 
reported a better 





patients to have 
failed outcome. 
 
A reduction of 
more than 50% in 
FI episodes was 
reported in 74.7% 
of the patients 
receiving active 
SNS treatment, 
where 10.3% of 
them were not 
satisfied after a 
median of 46 
months of follow-
up. 
The patients with IFI were clearly 
selected with justified requirements 
out of a large group of 342 patients 
with FI. The patients were a part of 
an international two-centre 
retrospective analysis of 
prospectively collected data in 
Denmark and The Netherlands. The 
authors clearly stated the definition 
of IFI and the exclusion criteria. A 
total of 129 patients were receiving 
active treatment with SNS, and the 
remaining 29 were identified. A 
systematic flow chart was presented 
to identify patients lost through the 
study and why. Patients were 
followed-up with a median of 46 
months. 
 
The authors state that a weakness 
with this study was that it was not 
possible to evaluate patient 
satisfaction and the relation to the 
bowel-habit diary as a function of 
time.  
 
The authors use both intention-to-
treat and per-protocol analysis and 
explains that the method of analysis 
has to be clearly stated in the future 
as it would make comparison from 
different centres more accurate.  
 
The authors present four options on 
how to optimize functional outcome 
and improve patient satisfaction 
with SNS therapy. 
 
Social behaviour is not addressed in 
the bowel-habit diary. The authors 
recommend that this should be 
included in future research as this 
study showed that SNS treatment 
increased patient satisfaction 
despite an increase in incontinence 
episodes at follow-up, compared to 
baseline.  
Conclusion 
The authors conclude 
that there is a clear 
relationship between 
improved continence and 
patient satisfaction. 
57.3% of patients with 
SNS therapy were 
satisfied at follow-up, and 
46% of patients with 
more FI episodes at 
follow-up then at 
baseline were also 
satisfied. Therefore, 
bowel-habit diaries and 
bowel scores cannot be 
the sole evaluation 
method for functional 
outcome of SNS therapy. 
 
Country 
Denmark, The Netherlands 
Year of data collection 
2000 - 2009 




Reference:  Rydningen M, Dehli T, Wilsgaard T, Rydning A, Kumle M, Lindsetmo RO, 
et al. Sacral neuromodulation compared with injection of bulking agents for faecal 
incontinence following obstetric anal sphincter injury - a randomized controlled trial. 
Colorectal Dis. 2017;19(5):O134-O44. 
Design:  RCT 
Level of documentation: 1b 
GRADE: B 
Objective Material and method Results Discussion/comments 
The study aims to compare the 
effects of sacral nerve 
modulation (SNM) versus 
submucosal injection of 
collagen (Permacol) in women 
with previous obstetric anal 
sphincter injuries (OASIS) that 
has led to faecal incontinence 
(FI). 
The study included 
women with FI related 
to OASIS (3rd or 4th 
degree tears) from two 
different hospitals in 
Norway.  
 
Inclusion criteria was FI 
defined by a St. Mark’s 
score >8 and weekly 




Women with a positive 
percutaneous nerve 
evaluation test (3 weeks 
testing with ³50% 
reduction in FI episodes) 
were randomly divided 
into a SNM-group and a 
Permacol-group.  
 
A change in St. Mark´s 
score between baseline 
and 6 months was the 
primary outcome, and 
changes in scores of 




58 women was eligible 
for the study, where 30 
were treated with SNM 
and 28 were treated 
with Permacol.  
 
In the SNM-group there 
was an 11.2 (SD 5.3) 
reduction in St. Mark’s 
score between baseline 
and 6 months. The 
Permacol-group showed 
a reduction of 2.3 (SD 
5.0) in St. Mark’s score.  
 
There was also a 
reduction in St. Mark’s 
score with regards to 
the secondary outcomes 
(quality of life and 
urinary incontinence).  
This is the first single blinded, parallel 
RCT that compares SNM and perianal 
bulking injections for treatment of FI 
following OASIS. The objective of the 
study is well defined. The women 
with a positive PNE-test were 
randomized into two groups (n = 30, 
n = 28), and then treated with either 
SNM or Permacol.  
 
Eligible women included in the study 
are presented in a flow-chart, and 
the authors justifies the women not 
included to the enrolment and 
randomization. 
 
The minor adverse effects of the two 
treatments are accounted for.  
 
Authors identify bias in favour of 
SNM since a positive PNE is an 
inclusion criteria. They describe 
additional analysis performed to 
overcome inherent selection bias via 
a worst-case scenario, which did not 
affect outcome. 
 
It is also mentioned that there was an 
imbalance in recruitment between 
the two hospitals, but an additional 
sensitivity analysis did not show 
change in outcome. 
 
The study focused on FI, but 
discovered that SNM could be used in 
treatment for double incontinence, 
as well as sexual dysfunction.   
Conclusion 
Authors conclude that SNM is a 
better alternative in treatment 
of FI in women with OASIS than 
Permacol. This is based on 
reduction in St. Mark’s score 
and scores evaluating quality of 
life and urinary incontinence. 
 
Permacol should not be 
considered when treating 
women with FI with a pervious 




Year of data collection 
2012-2014 
